Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523519 | 0.84 | L3MBTL1 (0.53) | L3MBTL1KDM1ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5961831 | 0.83 | HTR2C (0.50) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL9340707 | 0.83 | L3MBTL1 (0.46) | L3MBTL1KDM1ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9484876 | 0.83 | L3MBTL1 (0.53) | L3MBTL1KDM1AALDH1A1MEN1POLB | |
| SCHEMBL1539296 | 0.83 | L3MBTL1 (0.53) | L3MBTL1KDM1ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL878692 | 0.82 | FAAH (0.53) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL16440282 | 0.81 | CACNA1C (0.59) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL2053269 | 0.81 | NQO1 (0.52) | L3MBTL1KDM1ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL130839 | 0.81 | KDM1A (0.51) | L3MBTL1KDM1ATDP1ALDH1A1MEN1 | |
| SCHEMBL8232376 | 0.81 | HTT (0.48) | L3MBTL1KDM1ACYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2022161416-A1 | AROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 武汉朗来科技发展有限公司 | 2022-08-04 | — | — | WO | disclosed |
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-02-17 | — | — | US | disclosed |
| EP-3666769-A1 | NOVEL CASPASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019244066-A2 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-12-26 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2006038112-A1 | USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040106039-A1 | nonaqueous electrolytic solution containing a compound that is oxidized at a voltage > a charge end voltage of the battery and a compound which inhibits reactions at voltages < the charge end voltage | ARAI JUICHI (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030003370-A1 | Nonaqueous electrolytic solution containing a compound which is oxidized at a voltage higher than a charge end voltage of the lithium secondary battery and a compound which inhibits reactions at voltages lower than said charge end voltage. | HITACHI, LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| EP-1258939-A2 | Lithium secondary battery | Hitachi, Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-0401167-B1 | Process for the preparation of titanocenes with o,o'-difluoro ligands | CIBA GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| US-5075467-A | Reacting organotitanium halide with lithium amide | CIBA-GEIGY CORPORATION (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0401167-A2 | Process for the preparation of titanocenes with o,o'-difluoro ligands | CIBA-GEIGY AG (CH) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | L3MBTL1 3772/4885KDM1A 839/4885CYP1A2 1331/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | L3MBTL1 4289/4885KDM1A 702/4885CYP1A2 84/4885 |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | BRD3, BRPF3, EP300 | L3MBTL1 1450/4885KDM1A 81/4885CYP1A2 4776/4885 |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | TEK, TEKT1, EPCAM | L3MBTL1 846/4885KDM1A 3813/4885CYP1A2 4667/4885 |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | L3MBTL1 2848/4885KDM1A 4278/4885CYP1A2 1149/4885 |
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | MAPK11, WEE1, NOS1 | L3MBTL1 4856/4885KDM1A 3656/4885CYP1A2 1544/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | L3MBTL1 4204/4885KDM1A 3562/4885CYP1A2 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.